* Metacrine Inc MTCR.OQ MTCR.O is expected to show no
change
in quarterly revenue when it reports results on March 16
(estimated).
* Refinitiv's mean analyst estimate for Metacrine Inc is
for a
loss of 63 cents per share. For the same quarter last year, the
company reported a loss of $1.15 per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Metacrine
Inc is
$8.25, above its last closing price of $0.47.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.61 -0.61 -0.69 Missed -13.1
Jun. 30 2021 -0.61 -0.60 -0.59 Beat 2.1
Mar. 31 2021 -0.49 -0.51 -0.57 Missed -12.5
Dec. 31 2020 -0.36 -0.38 -1.15 Missed -202.6
Sep. -0.41 -0.41 -1.41 Missed -243.9
30 2020
This summary was machine generated March 14 at 13:10 GMT. All
figures in US dollars unless otherwise stated